Further, 5 μM E966-0530-45418 treatment inhibited EMT protein and mRNA expression more potently than the commercial CDK8 inhibitor senexin A and the clinical IPF drug pirfenidone (Figure 3A-J). Here, CDK8 is linked to idiopathic pulmonary fibrosis.